Biowaiver and Bioequivalence workshop

18th -19th May at Radisson blu, Hyderabad

Event Video

Focusing on complex generics

Even though there are clearly defined guidelines on biowaivers, Indian companies are facing challenges in achieving the desired results. The main challenges for these include achieving biowaivers for complex generics and modified release products, interpretation of dissolution tests, lack of success stories for reference, stringent review process, characterization and identifying expectations of regulatory authorities.

Based on these challenges and the immense potential that lies in approvals of these specific products, Treffen media brings you a comprehensive two-day workshop with former USFDA Director and MHRA senior assessor who have been a part of the drafting committee of some of these guidelines. Our experts will bring you drug specific case studies and clarify the regulatory authorities’ perspective and expectations to help you secure faster and hassle free approvals.

Event highlights

  • Former USFDA and MHRA trainers
  • Case studies on each perspective
  • Dissolution tests and interpretation as per regulatory norms
  • One on one QnA opportunity
  • Special focus on complex generics and modified release products
  • Guidance on orphan drugs and highly variable drugs

Who should attend

Biowaivers and Bioequivalence workshop is a comprehensive platform for all teams working in pharma and bio-pharma companies working on complex and non complex drug products. The agenda has been specially designed for professionals who are facing challenges in submissions and achieving biowaivers for their immediate release and modified release drug products.

Scientists, Managers, Directors and Heads working in:

Regulatory affairs

Our USFDA and MHRA experts will update you on the rationale behind the guidance and the latest regulatory updates and expectations of the region specific regulators.

Research and development

Specific case studies covering complex generics in both solid oral dosage forms and other delivery modes will help you get practical solutions to your drug delivery challenges.

Analytical development

Techniques and challenges associated with analytical development while conducting dissolution testing and stability testing. Critical review of each of the technique in accordance with regulatory expectation.


Biowaivers, BA/BE studies and IVIVC correlation are an important performance indicators to assure batch to batch quality and define process validation.

Meet Speakers

Dr. Mansoor A. Khan

Dr. Mansoor A. Khan

Former Director, Division of Product Quality Research and SBRS Scientist, CDER, FDA and Professor and Vice Dean, Presidential Impact Fellow, Texas A&M University, Rangel College of Pharmacy

Dr. Mansoor A. Khan served for over 11 years as the Director of Product Quality Research and a Senior Biomedical Research Scientist (SBRS) at CDER in US FDA where he led research teams on biotech products and small molecules, chemistry and stability, drug delivery systems and bioavailability/bioequivalence, and chemistry review teams of new and generic drugs for several complicated products.
He has received FDA/CDER 2015 outstanding ANDA reviews award, over ten FDA/CDER Team Excellence Awards, FDA/CDER Scientific Achievement Award, and FDA/CDER Exemplary Performance Awards, outstanding alumni award from St. Johns University, College of Phamacy, Excellence Award from Texas A&M.
He is a registered pharmacist, and earned his Ph.D. degree in Industrial Pharmacy from the St. John’s University School of Pharmacy in 1992. He has published over 275 peer-reviewed manuscripts, five texts including “Pharmaceutical and Clinical Calculations” and “Quality by Design for Biopharmaceutical Drug Product Development, 25 book chapters, 250 poster presentations, and more than 250 invited presentations world-wide. Dr. Khan’s research focus is primarily in the area of formulations design and development, and biopharmaceutics. He led the FDA new drug review team that approved the first 3D product on Aug 3, 2015

Dr Muhaned Al-Hindawi

Dr Muhaned Al-Hindawi

Former Senior Pharmaceutical Assessor, MHRA and Managing Director and Principal Consultant, Ontarget Pharma Consultancy

Dr Muhaned is currently the managing director and principal consultant of “Ontargetpharma Consultancy”, London UK prior to that he worked as a Senior Pharmaceutical Assessor with MHRA for more than 10 years. During his tenure at MHRA, he made several break-through issues affecting the common understanding by the agency and applicants. To mention a few –

  • The dissolution performance of multiple- strengths of oral solid dosage forms and how biowaiver can be applied
  • Effect of excipient on the bioavailability of API from aqueous oral solution and biowaiver criteria
  • Technical and quality standards of Vitamin D3 as API and finished product.

Prior to joining MHRA he occupied many technical posts in the pharmaceutical industry with over 20 years of hand on experience in new product development, construction of method of analysis with special interest in HPLC, Stability & kinetics, as well as in technology transfer, and process validation.
He holds a Ph.D. degree from UK, University of Wales, Cardiff, “Effect of Solvent on the Bioavailability of Testosterone Propionate from Oily Injections” and is also a member of the Royal Pharmaceutical Society of GB, pharmaceutical society of NZ and a registered pharmacist in UK.

Dr. Ajaz Hussain

Dr. Ajaz Hussain

President, NIPTE and Principal, Insight Advice & Solutions LLC

Ajaz is a globally recognised leader in pharmaceutical quality and is one of the most influential‘Medicine Maker’ (named in the 100 Power list by the UK’s Medicine Maker magazine in 2015). He trained at the Bombay College of Pharmacy (B. Pharm, 1981) and received an interdisciplinary doctoral degree from University of Cincinnati (1986). He began his career as Assistant Professor of Pharmacy at the Ohio Northern University and in 1989 he returned to University of Cincinnati as Research Assistant Professor of Pharmaceutics. He was promoted to Associate Professor (1992) and achieved tenure status in 1994. In 1995 he moved to the US FDA CDER as Branch Chief for Biopharmaceutics Research and thereafter was rapidly promoted with increasing oversight and policy development responsibilities in the area of product quality (Director Product Quality Research (DPQR) and then Director Office of Testing and Research). In 2000 he was promoted to the position of Deputy Director Office of Pharmaceutical Science and served under the Senior Biomedical Research Service (SBRS – a track under the Public Health Service Act). His contributions at FDA range from research on specific topics (such as the Biopharmaceutics Classification System Guidance) to global policy development (such as ICH Q8) in the area of Quality by Design. He launched and led the FDA’s PAT Initiative. He and his teams were recognized by two FDA Scientific Achievement Awards. In 2005 he moved to Sandoz (a division of Novartis Corp.) as Vice President and Global Head for Biopharmaceutical Development and contributed to this organization for achieving the industry leadership position in Biosimilars. He was then recruited by Philip Morris International (PMI) in Switzerland to develop adjacent business opportunities (tobacco plant-based vaccines) and to establish a rigorous scientific basis for tobacco harm reduction. At PMI he was promoted to the position of Chief Scientific Officer. For about a year he served as the Chief Scientific Officer and President Biotechnology at Wockhardt Ltd. He launched his consulting firm Insight Advice and Solutions LLC in July 2013. In October 2014, he was also appointed as the Executive Director of the National Institute for Pharmaceutical Technology and Education, a collaboration among pharmaceutical science and engineering programs at 17 major universities in the USA. He was elected President of NIPTE in February 2016. Ajaz is a Fellow of the American Association of Pharmaceutical Scientist and of the Swiss Society of Pharmaceutical Sciences.

Radisson Blu Plaza Hotel Hyderabad Banjara Hills

Radisson Blu Plaza Hotel Hyderabad Banjara Hills
8-2-409, Road Number 6, Banjara Hills, Hyderabad, Telangana 500034

Radisson Blu Plaza Hotel Hyderabad Banjara Hills

8-2-409, Road Number 6, Banjara Hills, Hyderabad, Telangana 500034

About Treffen Media

We Help you Build a Network that Promotes Learning, Sustainable Growth & Profitability

At Treffen Conferences our goal is to act as a catalyst for your business growth by bringing the best together. Which is why we focus on cutting edge research to bring the best content and best industry experts together at one platform to help you develop long lasting profitable relations.

Media Partners

pharmaVoice logo



PharmaVOICE magazine, reaches more than 41,000 qualified subscribers and 100,000 users with its digital edition. PharmaVOICE is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE provides readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including Social Media, WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts.

Chronicle Pharmabiz

Saffron Media Pvt. Ltd.

Media Company

Saffron Media Pvt. Ltd. is an independent media company headquartered in Mumbai, INDIA.
Focused primarily on print and online communications, our mission is to disseminate business critical information to professionals in the life sciences (Pharmaceuticals and Healthcare), food & beverage and hospitality sectors across South Asia. Our products include Ingredients South Asia (Magazine Fortnightly), Chronicle Pharmabiz (Newspaper Weekly), (Portal), Food & Beverage News (Newspaper Fortnightly), (Portal), (Portal).